Chan Cao, Ph.D.Chief Executive Officer at Assembly Medicine LLC
Dr. Cao seeks to tackle important problems across a wide range of biomedical sciences including ion channel mechanism, protein-drug interaction, and cancer immunotherapy. Her research interest is, more broadly, the question of how to fully harness the potential of human immunity against cancer. Following her curiosity, she started a project to use DNA precision assembly and antibody modules to redirect T cells against cancer cells in a highly flexible and potentially personalized way. This concept is known as nucleic acid-based protein-protein assembly (NAPPA), which can completely change the way multi-specific antibodies are made. This work was published in Advance Science 2019.
Dr. Cao received her Ph.D. degree at Nankai University in 2017, and she joined James Chou lab as an international PhD student at Harvard Medical School from 2014 to 2017. After obtaining her Ph.D. degree, Dr. Cao completed her postdoctoral training in the department of Biological Chemistry & Molecular Pharmacology at Harvard Medical School from 2017 to 2019. She left Harvard Medical School in 2019 for the Chief Executive Officer position in Assembly Medicine LLC, and she has got the independent PI position in Nankai University in 2021.